Kite Pharma (Gilead Sciences): High-Quality Service with Miltenvi
Kite Pharma, a leader in cell therapy and a wholly-owned subsidiary of Gilead Sciences, is committed to advancing innovative cancer treatments. Collaborating with T&L Biotechnology Co., Ltd., a pioneer in biopharmaceuticals, this partnership focuses on leveraging cutting-edge technology to enhance patient outcomes in oncology, Both companies share a vision of revolutionizing cancer care through the development of targeted therapies that harness the power of the immune system. By integrating Kite Pharma’s expertise in CAR T-cell therapies with T&L Biotechnology's robust research capabilities, a new generation of treatments is on the horizon. This collaboration aims to provide physicians with advanced solutions tailored to individual patient needs, driving significant improvements in the management of hematologic malignancies and solid tumors, With a commitment to innovation and patient-centricity, this partnership promises to set new standards in cancer treatment, ultimately transforming the lives of patients worldwide. Together, Kite Pharma and T&L Biotechnology are at the forefront of a healthcare revolution
- High-Quality Cell Expansion Process
- High-Quality Tcr-Engineered T Cells
- Custom Allogeneic Stem Cell Therapy
- Custom Cell Therapy Clinical Trials
- High-Quality Car-T For Solid Tumors
- Custom Cell Culture Media For Car-T
- Custom Car-T Cell Commercialization
- Custom Allogeneic Car-T Development
- Custom Next-Generation Gene Therapy
- High-Quality Car-T Cell Engineering